A Sodium Glucose Cotransporter-2 Inhibitor Prevents the Progression of Macrophage-driven Atherosclerosis Dependent on Glyceamic Control in Diabetic Apolipoprotein E-null Mice

被引：0
|
作者：
Terasaki, Michishige
Hiromura, Munenori
Kohashi, Kyoko
Kushima, Hideki
Nagashima, Masaharu
Mori, Yusaku
Hirano, Tsutomu
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
522-P
引用
收藏
页码：A134 / A135
页数：2
相关论文
共 18 条
  • [1] Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice
    Nogi, Yukinori
    Nagashima, Masaharu
    Terasaki, Michishige
    Nohtomi, Kyoko
    Watanabe, Takuya
    Hirano, Tsutomu
    PLOS ONE, 2012, 7 (04):
  • [2] Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice
    Masaharu, N.
    Nogi, Y.
    Terasaki, M.
    Notomi, K.
    Tomoyasu, M.
    Hirano, T.
    DIABETOLOGIA, 2012, 55 : S323 - S324
  • [3] Incretins directly suppress the development of macrophage-driven atherosclerosis in apolipoprotein E-null mice
    Hirano, T.
    Nagashima, M.
    Watanabe, T.
    Nohtomi, K.
    Terasaki, M.
    Miyazaki, A.
    DIABETOLOGIA, 2010, 53 : S72 - S72
  • [4] Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
    Terasaki, Michishige
    Hiromura, Munenori
    Mori, Yusaku
    Kohashi, Kyoko
    Nagashima, Masaharu
    Kushima, Hideki
    Watanabe, Takuya
    Hirano, Tsutomu
    PLOS ONE, 2015, 10 (11):
  • [5] The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
    Li, Zi
    Murakoshi, Maki
    Ichikawa, Saki
    Koshida, Takeo
    Adachi, Eri
    Suzuki, Chigure
    Ueda, Seiji
    Gohda, Tomohito
    Suzuki, Yusuke
    FEBS OPEN BIO, 2020, 10 (12): : 2761 - 2770
  • [6] Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, suppresses the progression of atherosclerosis in diabetic apoE-deficient mice
    Murakami, Saiko
    Matsumura, Takeshi
    Senokuchi, Takafumi
    Ishii, Norio
    Fukuda, Kazuki
    Yamada, Sarie
    Morita, Yutaro
    Nishida, Shuhei
    Sato, Miki
    Motoshima, Hiroyuki
    Kondo, Tatsuya
    Araki, Eiichi
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S99 - S99
  • [7] Glucose-Dependent Insulinotropic Polypeptide Suppresses the Development of Atherosclerosis in Apolipoprotein E-Null Mice Via Its Own Receptors
    Nagashima, Masaharu
    Terasaki, Michishige
    Nohtomi, Kyoko
    Tomoyasu, Masako
    Kaneyama, Shuri
    Watanabe, Takuya
    Miyazaki, Akira
    Hirano, Tsutomu
    DIABETES, 2011, 60 : A479 - A479
  • [8] Overexpression of PER2 inhibits the progression of atherosclerosis via the Akt-eNOS signaling in apolipoprotein e-null mice
    Su, Gang
    Sun, Guangli
    Liu, Hai
    Shu, Liliang
    Zhang, Jingchao
    Guo, Longhui
    Huang, Chen
    Xu, Jing
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (06): : 5950 - 5959
  • [9] Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice
    Terasaki, Michishige
    Nagashima, Masaharu
    Nohtomi, Kyoko
    Kohashi, Kyoko
    Tomoyasu, Masako
    Sinmura, Kyoko
    Nogi, Yukinori
    Katayama, Yuki
    Sato, Kengo
    Itoh, Fumiko
    Watanabe, Takuya
    Hirano, Tsutomu
    PLOS ONE, 2013, 8 (08):
  • [10] The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model
    Yoshioka, Naoki
    Tanaka, Miyako
    Ochi, Kozue
    Watanabe, Akiko
    Ono, Kenji
    Sawada, Makoto
    Ogi, Tomoo
    Itoh, Michiko
    Ito, Ayaka
    Shiraki, Yukihiro
    Enomoto, Atsushi
    Ishigami, Masatoshi
    Fujishiro, Mitsuhiro
    Ogawa, Yoshihiro
    Suganami, Takayoshi
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 140
12